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calibrating national surveillance data in the United 
Kingdom: the second study of infectious intestinal 
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Sarah J O'Brien*1, Greta Rait2, Paul R Hunter3, James J Gray4, Frederick J Bolton5, David S Tompkins6, Jim McLauchlin4, 
Louise H Letley2, Goutam K Adak4, John M Cowden7, Meirion R Evans8, Keith R Neal9, Gillian E Smith10, Brian Smyth11, 
Clarence C Tam12 and Laura C Rodrigues12
Abstract
Background: Infectious intestinal disease (IID), usually presenting as diarrhoea and vomiting, is frequently preventable. 
Though often mild and self-limiting, its commonness makes IID an important public health problem. In the mid 1990s 
around 1 in 5 people in England suffered from IID a year, costing around £0.75 billion. No routine information source 
describes the UK's current community burden of IID. We present here the methods for a study to determine rates and 
aetiology of IID in the community, presenting to primary care and recorded in national surveillance statistics. We will 
also outline methods to determine whether or not incidence has declined since the mid-1990s.
Methods/design: The Second Study of Infectious Intestinal Disease in the Community (IID2 Study) comprises several 
separate but related studies. We use two methods to describe IID burden in the community - a retrospective telephone 
survey of self-reported illness and a prospective, all-age, population-based cohort study with weekly follow-up over a 
calendar year. Results from the two methods will be compared. To determine IID burden presenting to primary care we 
perform a prospective study of people presenting to their General Practitioner with symptoms of IID, in which we 
intervene in clinical and laboratory practice, and an audit of routine clinical and laboratory practice in primary care. We 
determine aetiology of IID using molecular methods for a wide range of gastrointestinal pathogens, in addition to 
conventional diagnostic microbiological techniques, and characterise isolates further through reference typing. Finally, 
we combine all our results to calibrate national surveillance data.
Discussion: Researchers disagree about the best method(s) to ascertain disease burden. Our study will allow an 
evaluation of methods to determine the community burden of IID by comparing the different approaches to estimate 
IID incidence in its linked components.
Background
Infectious intestinal disease (IID), usually presenting as
diarrhoea and vomiting, is frequently preventable. Its
commonness makes it an important public health prob-
lem. In the mid 1990s around 1 in 5 people in England
were found to suffer from IID, with around 35,000 hospi-
tal admissions and 300 deaths annually, an estimated
annual cost to the nation of £0.75 billion [1]. Although
IID is very common in the community, not all cases pres-
ent to the healthcare system, and not all cases that pres-
ent are reported to national surveillance. Many IID cases
are therefore not captured by routine data sources, a pat-
tern described as the surveillance pyramid (Figure 1).
Routinely available surveillance data in the United King-
dom, and elsewhere, thus underestimate the total IID
burden, and that degree of underestimation needs to be
calibrated [1].
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Most studies for estimating community disease burden
in developed countries are either prospective cohort
studies or retrospective cross-sectional surveys. The pro-
spective cohort design consists of recruiting volunteers
and asking them to record relevant symptoms, often in
some form of diary. The retrospective study involves con-
tacting people, usually by telephone and asking about
symptoms in the recent past. A major advantage of popu-
lation-based, prospective cohort studies is the ability to
request stool specimens from people who report illness
so that the range of gastrointestinal pathogens causing
symptoms can be determined. Retrospective study
designs provide no information on the microbiological
causes of illness (a major weakness) but are significantly
quicker and less costly to complete.
Our present study builds on a previous study of IID
conducted in England during the early 1990s, which
underlined the public health impact of gastrointestinal
infection [1]. At that time, approximately 20% of the pop-
ulation was found to suffer from IID annually.
The only other notable prospective study to date, based
on active detection of IID, was conducted in the Nether-
lands. Whilst in England there were an estimated 194
cases of infectious intestinal disease (IID) per 1,000 per-
son years (equivalent to 0.2 per person per year) [1], in
the Netherlands there were 283 cases per 1000 person
years (equivalent to 0.3 per person per year) [2]. Although
the two studies shared some common methods, the case
definitions differed.
A major contribution of the IID study in England was
calibration of the national surveillance system, i.e. esti-
mating the factor by which the reported number of infec-
tions with specified pathogens needed to be multiplied in
order to establish the actual number of infections in the
community. For every case of IID reported to national
surveillance, 136 cases had occurred in the community.
For campylobacters it was estimated that the ratio of
cases in the community to those reported to national sur-
veillance was 8 to 1. For salmonellas and noroviruses the
corresponding ratios were 3 to 1 and over 1,500 to 1
respectively [1].
By contrast there are many more retrospective studies
reported in the literature, mainly from North America
[3]. These retrospective studies have been used in both
outbreak and non-outbreak settings [4-8]. The studies
have varied in their estimation of illness rates from 0.6 to
3.2 episodes per person year, though case definitions
often differed from one study to another. For example, in
the US, the overall prevalence of self-reported acute diar-
rhoea in the four weeks before telephone interview in
randomly selected residents from defined catchment
areas was 11% or 1.4 episodes of diarrhoea per person per
year [6]. In Australia, in a cross-sectional telephone sur-
vey of randomly selected individuals, 11.2% of respon-
dents reported gastroenteritis with an overall weighted
incidence of 0.92 (95%CI 0.77-1.6) cases per person per
year [9].
The problem is that estimates of disease burden in the
community differ substantially between retrospective and
prospective study designs even when using identical case
definitions. This was highlighted in original the IID Study
where the retrospective element of the study estimated
disease incidence at 0.55 episodes per person per year
and the prospective element at 0.19 [10]. At the time this
discrepancy was attributed to "telescoping" whereby peo-
ple remember disease episodes as being more recent than
they actually are, thereby inflating the incidence over the
recall period. Further concerns about the validity of ret-
rospective surveys of diarrhoeal incidence were raised in
a study centred on a waterborne outbreak [11].
However, a number of explanations, in addition to tele-
scoping, might explain the discrepancy in incidence rates
derived from prospective and retrospective studies.
Potential issues with active reporting in population-based
prospective cohort studies include loss to follow-up, sen-
sitisation and reporting fatigue. In the IID Study in Eng-
land 39% of the original cohort of 9,296 were lost to
follow-up over 6 months and it is not clear whether loss
to follow-up might be correlated with risk of illness. Sen-
sitisation occurs when respondents become more aware
of their health because they are participating in a health-
related study [12], and may perceive more symptoms dur-
ing early follow-up than before enrollment. If they subse-
quently become fatigued with completing a health diary,
or returning data via postcard or e-mail, the number of
Figure 1 The surveillance pyramid illustrating attrition of data at 
each level.
Data 
appear in 
national 
statistics 
Positive laboratory test results 
People who provide faeces 
sample requested by GP 
People who go to their GP with IID 
and are asked to provide a sample 
People in the community with IID 
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symptoms reported over time may decline [12,13]. This
pattern of sensitisation-fatigue, where illness reporting is
highest during the early weeks of follow-up and subse-
quently decreases, is characteristic of much longitudinal
data [12,14,15]. Fatigue might also have played a part in
the decline in data quality observed in some studies
[14,16-18]. Sensitisation and fatigue are potential prob-
lems because estimated incidence rates may vary as a
function of the length of the follow-up period if either of
these time-dependent conditioning effects is present [12].
For retrospective studies the main problem is accuracy
of retrospective reporting. This includes not only inaccu-
racy in the respondent remembering whether or not they
suffered the symptoms requested but whether they recall
other important information such as the date of onset of
symptoms, duration and severity. The potential issue of
telescoping, whereby people report illness that occurred
just outside the recall period as having occurred during
the recall period, so increasing the estimated disease inci-
dence, has already been raised. Conversely people might
be more likely to remember events that occurred close to
the interview, so reducing the estimated incidence.
A further issue with both study designs is the issue of
the representativeness of participants. Prospective stud-
ies can be designed to invite a representative sample of
the population according to whatever criteria the investi-
gators choose. However, in most studies a relatively small
proportion of those invited is actually recruited and it is
uncertain whether the symptoms under investigation dif-
fer between those who accept and decline the invitation.
By contrast telephone surveys are much more difficult to
target at a representative sample of the community,
though response rates are usually higher. Particular issues
of concern are the increasing proportion of homes with-
out access to a landline, especially amongst young adults
and people with jobs or lifestyles that mean they are away
from the home during times when most calls tend to be
made.
Another of the major challenges in international com-
parisons of IID incidence rates, regardless of the study
design, is the variation in case definitions. Indeed the
case definition can influence the observed incidence of
gastroenteritis by as much as 1.5-2.1 times in a given
country [19]. To overcome this, a standard, symptom-
based definition has been developed that should allow
international comparison in the future [19]. We have
included information in our clinical questionnaire that
will allow us to report rates according to the international
definition for both the telephone survey and the prospec-
tive cohort study.
Research Questions
During the past decade in the UK, reported rates of labo-
ratory-confirmed infections associated with IID appear
to have fallen. However, this may not reflect a true decline
in disease as there have been structural changes that
could affect national surveillance over the same time
period. In primary care, people seeking advice about IID
can now contact NHS Direct (or NHS24 in Scotland), a
24-hour, nurse-led, telephone helpline rather than con-
sult their general practitioner (GP). Clinical laboratories
no longer report directly to the national centre in Eng-
land but via regional units. The creation of the Health
Protection Agency in 2003 reduced from 48 to nine the
number of lead laboratories directly under the control of
the public health services with a possible reduction in the
range of microbiological tests applied to each specimen.
Conversely, there have been huge advances in the meth-
ods available to detect gastrointestinal pathogens, notably
the introduction of molecular methods. It is therefore
unclear whether the reported decline in IID is due to a
genuine reduction in incidence. Answering this question
is important in order to direct future food safety policy.
The principal research question in the Second Study of
Infectious Intestinal Disease in the Community (IID2
Study) is:-
• Has the incidence of IID in England in the commu-
nity declined since the mid 1990s?
The secondary research questions are:-
• What is the aetiology of IID in the community, and
presenting to GPs, and by how much do national sur-
veillance data in the UK underestimate the commu-
nity and GP burden of IID?
• How much IID is acquired abroad?
• How do molecular methods compare with tradi-
tional microbiological methods for IID diagnosis?
• What is the best research method for determining
IID incidence in the community?
Methods/Design
The IID2 study comprises seven separate but related
studies (Figure 2). All studies take place simultaneously
over a period of 12 months.
Case definition used in all studies
Cases are defined as persons with loose stools or clini-
cally significant vomiting lasting less than two weeks, in
the absence of a known non-infectious cause, preceded
by a symptom-free period of three weeks. Vomiting is
considered clinically significant if it occurs more than
once in a 24-hour period and if it incapacitates the case or
is accompanied by other symptoms such as cramps or
fever.
Exclusion criteria used in all studies
The exclusion criteria are:-
• Patients with terminal illness.
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• Patients whose first language was not English and
for whom a suitable interpreter was not available.
• Patients with severe mental incapacity.
• Patients with non-infectious causes of diarrhoea:
Crohn's disease, ulcerative colitis, cystic fibrosis, coe-
liac disease, surgical obstruction, excess alcohol,
morning sickness, regurgitation in infants. The rea-
son for these exclusions is because it is difficult to
determine dates of onset for acute IID in the presence
of chronic bowel disease.
Participant identification and recruitment
The first study is a UK-wide, all-age, telephone survey of
self-reported IID. It is a community-based, retrospective
survey with a target recruitment of 14,400 respondents.
Recruitment is via a two-stage sampling process. First,
households are selected at random from the populations
of the four countries of the United Kingdom through a
process of random digit-dialling of landlines. Second, in
homes where there is more than one family member who
could potentially take part, the participant is selected at
random by asking the person who answers the telephone
to invite the person in the household whose birthday
occurs next to take part in the study. The telephone sur-
vey takes place on weekday evenings, between 18:00 and
21:00 or on Saturday/Sunday between 14:00 and 17:00.
Each number is 'phoned three times (including at least
once at the weekend and once during the week) before
being deemed non-contactable. Respondents aged = 12
years are interviewed directly, and a parent or guardian is
Figure 2 The structure of the IID2 Study.
Yes                No
Prospective Studies Geographical area Retrospective Study
Study 1 Community (UK) Telephone Survey
Study 2 Prospective Cohort
84 General Practices (UK)
Study 3 GP Presentation Study 
(collecting samples from
42 General
Practices
every case) (UK)
Study 4 Validation Study
Study 5 GP Enumeration Study 42 General
(observing current clinical Practices (UK)
practice, not necessarily 
collecting samples in every
case).
Study 6 Microbiology Study State of the Routine tests at
(Laboratory -based) art tests local laboratory
Positive Negative
Study 7 Calibration Study Official Statistics
(National reporting study)
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interviewed about participants aged < 12 years. Oral
informed consent is obtained from all participants and
parents of children aged < 16 years. The telephonists
administer a standard questionnaire that includes clinical
history, history of recent foreign travel and any clinical
consultations, including those with NHS Direct (NHSD)
or NHS24 (in Scotland). All calls are recorded using
"CopyCall" software. To investigate whether accuracy of
symptom reporting varies according to the recall period,
we assign participants randomly to be questioned about
symptoms occurring either within the previous seven
days or 28 days.
The second study is a prospective, all-age, popula-
tion-based cohort study of self-reported IID. The sam-
pling frame is all 912 general practices in the UK that are
part of the Medical Research Council General Practice
Research Framework http://www.gprf.mrc.ac.uk/. We
mail study details to all the 912 practices to seek expres-
sions of interest. A minimum of 84 practices is required
(see section on Sample Sizes below). Trained nurses in
each participating practice generate a list of 800 potential
participants at random from the practice list with a view
to recruiting at least 100 participants per practice. This is
scrutinised by the general practitioner (GP) to ensure that
it is appropriate to contact the individuals. For example,
the GP checks that the list does not contain the name of
someone who is very frail or recently deceased.
The GP sends a letter to potential participants contain-
ing an invitation to take part and an information sheet
which explains the study and what is involved if they
agree. We ask participants to return a reply-paid slip to
their GP surgery indicating whether or not they wish to
discuss the study further with the practice research nurse.
If so, the nurse contacts them to arrange a suitable
appointment, explains the study in greater detail and, if
appropriate, obtains written consent. The participant also
completes a very short, baseline questionnaire requesting
basic demographic details of age, sex, address (including
post code) and occupation.
Participants are followed up weekly for one calendar
year from the date of recruitment to find out if they have
any episodes of IID. Follow-up is either by secure, auto-
mated e-mail or by weekly postcard, depending on the
participant's preference, and employs negative reporting;
participants are asked to reply each week even if they
have had no symptoms. Each participant is provided with
a faecal specimen kit (specimen pot, instructions on how
to obtain a specimen, reply-paid, Post Office approved
packaging), and a short symptom questionnaire with
reply-paid envelope.
Participants are reminded that, if they develop symp-
toms, they should send a sample promptly to the Health
Protection Agency Regional Laboratory in Manchester.
They also complete the symptom questionnaire, which
they return to the study team in the reply-paid envelope.
The symptom questionnaire asks about date of onset and
duration of symptoms, symptom profile and severity,
healthcare-seeking behaviour (including contact with
NHS Direct or NHS24, contact with or visits to the pri-
mary care team or visits to hospital and any overnight
stays) and history of foreign travel in the ten days before
symptom onset.
The third study is a prospective study of all patients
presenting to their GP with symptoms of IID (GP Pre-
sentation Study). This takes place in half the practices
that are undertaking the prospective cohort study. Any-
one registered in the practice who consults their GP for
an episode of IID is eligible to take part, unless disallowed
by the exclusion criteria (see above). The GP identifies
eligible patients and refers them to the practice research
nurse, who explains the study. Patients that agree to par-
ticipate complete a consent form, and are given a speci-
men kit (as described above), and a symptom
questionnaire with reply-paid envelope. The participant
provides the sample and completes the questionnaire at
home, posting them back to the study team using the
reply-paid envelopes.
The fourth study is an audit of the IID2 study recruit-
ment process (GP Validation Study). Using a stan-
dardised, pre-defined set of diagnostic codes (Read codes
[20]) the research nurse searches the practice database
for every patient that presents with IID during the study
period. They cross-reference this list with the cases
recruited to the GP Presentation Study to determine the
proportion of eligible participants that are not recruited.
This will allow adjustment for under-ascertainment at the
end of the study.
The fifth study is a survey of routine clinical practice
for IID and of organisms identified in IID in routine
laboratory practice (GP Enumeration Study). It is con-
ducted in the practices not undertaking the GP Presenta-
tion Study. The practice research nurse identifies from
the practice database all patients who present with a new
episode of IID during the study period. They record the
case's age, sex, postcode, and information about the place
of consultation, admission to hospital and whether or not
a faecal specimen has been requested. If a sample was
requested as part of the consultation the nurse records
the result. By comparing the results of the GP Presenta-
tion and Enumeration Studies we will determine the rela-
tionship between the total number of people who consult
their GP with IID and the number of people who consult
with IID and have their infection laboratory confirmed in
routine clinical practice (which we anticipate will be
smaller).
The laboratory-based studies take place at the Health
Protection Agency (HPA) Regional Laboratory in Man-
chester and the HPA Centre for Infections in London. All
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faecal specimens from the prospective Cohort Study and
the GP Presentation Study are examined first at the Man-
chester laboratory using conventional microbiological
methods (Table 1).
All specimens are tested on the day of receipt. An initial
10% suspension of the stool specimen is made in 0.1%
peptone water and used to inoculate the various selective
plating media and enrichment broths. At this stage the
specimens are cultured for Campylobacter jejuni/coli,
Escherichia coli O157, Listeria monocytogenes, Salmo-
nella species, Shigella species and Yersinia species. They
are also examined by enzyme-linked immunoassay (EIA)
for Clostridium perfringens enterotoxin, Clostridium dif-
ficile toxins A and B, Cryptosporidium and Giardia and
by light microscopy for Cyclospora.
We use two approaches for detecting viruses. Speci-
mens from children <5 years old are examined for Rotavi-
rus and Adenovirus 40, 41 by immunoassay. This is
routine clinical practice, which supports clinical manage-
ment of the participants. All samples are then examined
for the five major viral pathogens by quantitative poly-
merase chain reaction, which has meant developing suit-
able methods for assigning positive results based on cycle
threshold values [21,22].
As part of the routine diagnostic algorithm, specimens
from patients with a history of foreign travel are also
tested for Vibrio spp. and for the ova and cysts of para-
sites using National Standard Methods (BSOP30 and
BSOP31 (available at http://www.hpa-standard-
methods.org.uk/national_sops.asp)). If the patient is con-
sidered to be part of a potential food poisoning outbreak
the specimens are cultured for Clostridium perfringens,
Staphylococcus aureus and Bacillus species using
National Standard Methods (BSOP30). All isolates of the
major enteric bacteriological pathogens are submitted to
the HPA Centre for Infections for strain characterisation.
Specimens are batched and sent from Manchester to
the HPA Centre for Infections by courier twice a week.
Two nucleic acid extracts are prepared from each sample
of faeces by a modification of the method of Boom and
colleagues [23]. For one sample (DNA) mechanical dis-
ruption using zirconia beads is included [24], and in the
second, RNA is immediately converted to cDNA through
random primed reverse transcription [25]. The reverse
transcriptase reactions using random hexamer priming
have been described elsewhere [26-28]. Each extract is
examined by real-time PCR for a range of potential
pathogens (Table 2). These are Campylobacter jejuni,
Campylobacter coli, Clostridium perfringens, Clostridium
difficile, Listeria monocytogenes, Salmonella species,
rotavirus, norovirus, sapovirus, adenovirus, astrovirus,
Cryptosporidium, Giardia and E. coli (enteroaggregative
and verocytotoxigenic (genes encoding VT1 and VT2)).
A PCR result is considered to be positive if the cycle
threshold value (CT value) is less than 40. Specimens that
Table 1: Target Organisms: Primary Diagnostic Methods.
Bacteria Methods
Campylobacter 
jejuni/coli*
Direct plating - modified cefeoperazone, charcoal 
deoxycholate (CCD) agar.
Enrichment culture - Preston broth.
Clostridium 
perfringens 
(enterotoxin)
Techlab™ (Blacksburg, USA) enzyme linked 
immunosorbent assay (ELISA), all positives to be 
cultured and isolates sent to the reference 
laboratory.
Clostridium 
difficile cytotoxin
Premier™ (Meridian Bioscience Inc., Cincinnati, OH) 
toxins A and B enzyme immunoassay (EIA)
Escherichia coli 
O157*
Direct plating on Cefixime Tellurite Sorbitol 
MacConkey agar.
Enrichment in Modified Tryptone Soya Broth with 
Novobiocin.
Listeria spp 
(monocytogenes)*
Direct plating - polymyxin acriflavine lithium chloride 
ceftazidime asculin mannitol (PALCAM) agar**
Salmonella spp* Direct plating - Xylose Lysine Dextrose (XLD) Agar 
and Desoxycholate Citrate Agar (DCA).
Enrichment culture - Selenite F broth and Rappaport 
Vasilliades Salmonella enrichment broth.
Shigella spp* Direct plating - XLD and DCA.
Yersinia spp* Direct plating - Cefsulodin Irgasin Novobiocin (CIN) 
selective agar.
Enrichment culture - Tris Buffer Yersinia enrichment 
broth.
Protozoa
Cryptosporidium 
parvum
Techlab™ Giardia/Cryptosporidium check, r-
biopharm™ RIDA™ Quick Cryptosporidium
Giardia intestinalis Techlab™ Giardia/Cryptosporidium check, r-
biopharm™ RIDA™ Quick Giardia
Cyclospora Modified Ziehl-Neelsen (ZN) stain
Viruses
Enteric viruses (Premier™ Rotaclone, Premier™ Adenoclone).
* All positive isolates were sent to the relevant reference laboratory.
** PALCAM agar was used in previous studies [32,33]
Notes:
1. If the clinical information indicated a history of foreign travel then 
specimens were tested for Vibrio spp (Direct plating using 
Thiosulphate Citrate Bile Sucrose (TCBS) agar and alkaline peptone 
water (APW) enrichment) and ova, parasites and cysts (Direct and 
concentration microscopy)
2. If the specimen was related to an outbreak investigation then it was 
tested for other pathogens e.g. Staphylococcus aureus (Direct plating 
MSA), Bacillus spp. (direct plating Bacillus cereus agar - MEYP).
3. Specimens from children < 5 years old were examined for Rotavirus 
and Adenovirus 40,41 by immunoassay (Premier™ Rotaclone, 
Premier™ Adenoclone).
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Table 2: Assays used to detect a range of bacterial, viral and parasitic pathogens.
PCR (SOP) Assay - chemistry Target Organism Gene encoding proteins References
NOR1 SINGLE-5'exonuclease Norovirus genogroup 1 RNA dependent RNA 
polyermerase/capsid
[34]
NOR2 DUPLEX-
5'exonuclease
Norovirus genogroup 2
Mengo virus mutant vaccine 
strain MC
RNA dependent RNA 
polyermerase/capsid
Not known
[35]
Comite Europeen de 
Normalisation (CEN)
ROTA SINGLE-5'exonuclease Rotavirus Group A Viral Protein 6 [35,36]
SAPO DUPLEX-
5'exonuclease
Sapovirus Polymerase-capsid 
junction (2 probes)
[37]
ASTR SINGLE-SYBR Green Astrovirus Capsid [38]
ADEN SINGLE-5'exonuclease Adenovirus type 40 and 41 Long fibre protein [39]
CAMP DUPLEX-
5'exonuclease
C. jejuni
C. coli
Membrane associated 
protein
Lipoprotein of iron 
binding protein
[40]
SALM DUPLEX-
5'exonuclease
Salmonella enterica
Green Fluorescent Protein 
gene (gfp) inserted into a E. coli
Glycotransferase
GFP Protein
[41]
EAGG SINGLE-5'exonuclease EnteroAggregative E. coli Anti aggregation 
transporter
[28,42]
LIST SINGLE-5'exonuclease Listeria monocytogenes Haemolysin A [43]
VT1-VT2 DUPLEX-
5'exonuclease
Verocytotoxin 1
Verocytotoxin 2
Verocytotoxin 1
Verocytotoxin 2
[44]
GIAR SINGLE-5'exonuclease Giardia spp. Elongation Factor 1 alpha [43]
CRYP DUPLEX-
5'exonuclease
C. hominis, C. parvum, C. 
meleagridis, C. felis
Cryptosporidium oocyst 
wall protein
[43]
CPER DUPLEX-
5'exonuclease
C. perfringens alphatoxin and 
enterotoxin
Phospholipase C gene of 
C. perfringens
Enterotoxin gene of 
enterotoxigenic C. 
perfringens
[45]
CDIF MULTIPLEX-
5'exonuclease
Toxin-producing C. difficile Toxin B gene (tcdB), 
binary toxin (cdt), and 
tcdC gene single-base 
deletion at nucleotide 
117 (tcdB)
[46-48]
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are PCR-positive for C. difficile toxin are cultured and the
isolates are ribotyped.
Two samples of 1-2ml each of a 10% faecal suspension,
5 × 10 μl of a DNA extract and 5 × 10 μl of cDNA extract
are archived for future study. Participants in the study
give their explicit consent for this.
Finally, in the National Reporting Study, we calibrate
national surveillance data to determine the relationship
between disease burden in the community and infections
reported to national surveillance. To do this we correlate
reports of laboratory-confirmed IID due to the target
pathogens in the IID2 Study firstly with self-reported IID
in the Cohort Study, secondly with telephone calls to
NHS Direct or NHS 24 for people reporting IID, and
thirdly with patients consulting for IID in the GP Presen-
tation Study. Each of the studies described above provides
a slice through the surveillance pyramid (Figure 1). By
comparing rates and aetiology at each level of the pyra-
mid we can determine by how much national surveillance
data underestimate IID burden in the community.
Sample Sizes
The sample size calculations for the telephone survey,
prospective cohort study and GP Presentation Study are
presented in Tables 3, 4, and 5 respectively. The assump-
tions used in the sample size calculations are presented in
each table.
Plan of Analysis
The proposed analytical strategy is as follows:-
Methods for assessing representativeness, response bias,
compliance and list inflation for the prospective study and
the telephone survey.
Representativeness
Representativeness of the Cohort Study and Telephone
Survey sample will be assessed by comparing characteris-
tics of the respective study populations with routine
National Census data on age distribution, sex, ethnic
group, urban-rural residency, socioeconomic group, and
area-level deprivation. For the GP Presentation Study,
representativeness of the population of participating
practices will be assessed by comparing the age and sex
distribution of the registered population with that of the
census.
Compliance
Compliance in the Cohort and GP Presentation Studies
will be calculated as the proportion of participants
reporting symptoms who submit a questionnaire and
stool sample. Differences in compliance across age, sex
and socioeconomic group will be assessed with the Pear-
son chi-square test and multivariable logistic regression.
Under-ascertainment
Factors influencing under-ascertainment in the GP Pre-
sentation Study will be investigated using multivariable
logistic regression. The inverse of the predicted under-
ascertainment from this model will be used as a multi-
plier for the number of cases identified in the GP Presen-
tation Study.
Overall incidence of IID
a. The overall incidence rate of IID in the community will
be calculated from the total number of cases reported in
the Cohort Study and the follow-up time of members of
the cohort.
b. The overall incidence rate of IID presenting to gen-
eral practice will be calculated from the total number of
cases reported in the GP Presentation Study, adjusted for
under-ascertainment, and in the Enumeration Study, and
the follow-up time of all persons registered in the practice
populations. Adjustments will be made to the denomina-
tor (practice list size) of the GP presentation rates to
adjust for list inflation.
c. For the Telephone Survey, annualised rates of IID in
the community, presenting to general practice and con-
tacting NHS Direct/NHS 24 will be estimated separately
for one month and one week recall periods, after adjust-
ment for seasonality, separately for each of the four coun-
tries, and for the UK overall.
All incidence estimates will be standardized to the UK
census population to enable comparison.
Prevalence of aetiological organisms in IID cases and 
pathogen-specific incidence
The prevalence of each pathogen among IID cases will be
estimated by calculating the proportion of specimens
tested that are positive for that organism. This will be
done separately for the Cohort and GP Presentation stud-
ies.
Table 3: Sample size calculations for estimating the overall frequency of IID via self-report telephone survey.
Duration of recall period Incidence in original IID 
recall Questionnaire
Widest acceptable CI limit Number needed to survey
28 days 6% 4% 500
7 days 1.5% 1% 2500
Note: Based on an expected frequency of IID of 6%, with a 95% Confidence Interval (CI) of 4% to 8%. Allowing for differentials in response rate 
the number needed to survey was increased by 20% i.e. to 600 for recall over one month and 3000 for recall over one week.
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For organisms for which both conventional and molec-
ular diagnostic methods are used, the performance of the
two methods will be compared.
Pathogen-specific prevalences will be used to deter-
mine the number of cases positive for that organism
expected in the Cohort and GP Presentation studies,
adjusted for non-compliance in submitting a stool speci-
men and under-ascertainment. Adjustments will be made
assuming that the observed distribution of organisms is
representative of all IID cases. These adjusted numera-
tors will then be used to estimate the incidence of IID for
each pathogen, both in the community and presenting to
general practice. Confidence intervals will be calculated
Table 4: Sample size calculations for prospective cohort study estimating a single UK-wide pyramid.
England Wales
Organism/
condition
Baseline 
incidence1
Reduction to 
be detected
Person-years GP practices Person-years GP practices
All IID 19.20% 20% 2,000 20 200 2
Severe cases* 6.00% 20% 7,000 70 400 4
Campylobacter 0.87% 20% 500,000 5,000 2,400 24
Salmonella 0.22% 20% 500,000 5,000 9,500 95
Campylobacter+
Salmonella
1.10% 20% 200,000 2,000 2,000 20
Campylobacter+
Salmonella+ C. 
perfringens
1.34% 20% 100,000 1,000 1,600 16
Scotland Northern Ireland UK
Organism/
condition
Person-
years
GP practices Person-years GP practices Person-years GP practices
All IID 200 2 65 1 2,465 25
Severe cases* 700 7 300 3 8,400 84
Campylobacter 4,200 42 1,400 14 508,000 508
Salmonella 16,400 164 5,500 55 531,400 532
Campylobacter+
Salmonella
3,400 34 1,200 12 206,600 207
Campylobacter+
Salmonella+ C. 
perfringens
2,800 28 1,000 10 106,200 107
* Severe cases are defined as those presenting to primary care
Note: Based on ability to detect a 20% decrease in incidence with 80% power and 95% precision. Required number of person-years and GP 
practices (recruiting 100 patients from each practice) by country, based on the relative populations of the 4 UK countries
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by a method that does not increase the apparent preci-
sion due to this adjustment.
Clustering
Practice-level variation in rates will be analysed using
Poisson regression. Over-dispersion in GP presentation
rates will be modelled with a random effects term at the
practice level. Any observed clustering effect will be
incorporated into all confidence intervals applied to GP
presentation rates. Analysis will be based on episodes
(IID symptoms separated by a symptom-free period of
three weeks) rather than individuals, assuming each epi-
sode to be independent.
Reporting pyramids will be calculated from the overall
incidence rates in the community and presenting to GPs
by considering the ratios between these rates. Performing
the same calculation on the upper and lower confidence
intervals for the rate at each stage will derive the upper
and lower sensitivity bands. The ratio of community rates
to nationally reported cases will be calculated by project-
ing the overall cohort and presentation incidence rates to
the population and comparing these to that reported to
the laboratory reporting surveillance system over the
same period. When more than one laboratory method
was used, these will be estimated separately for results
Table 5: Sample size estimates for GP Presentation Study estimating a single UK-wide pyramid.
England Wales
Organism Baseline 
incidence*
Reduction to 
be detected
Person-years GP practices Person-years GP practices
Campylobacter 4.10% 20% 115,000 20 7,000 2
Salmonella 0.16% 50% 41,000 7 3,000 1
Salmonella 0.16% 40% 67,000 12 4,000 1
Salmonella 0.16% 30% 127,000 22 8,000 2
Salmonella 0.16% 20% 302,000 51 18,000 3
C. perfringens 0.13% 20% 364,000 61 22,000 4
Scotland Northern Ireland UK
Organism Person-years GP practices Person-years GP practices Person-years GP practices
Campylobacter 12,000 2 4,000 1 138,000 25
Salmonella 5,000 1 2,000 1 51,000 10
Salmonella 7,000 2 3,500 1 81,500 16
Salmonella 13,000 3 4,500 1 152,500 28
Salmonella 31,000 6 10,500 2 361,500 62
C. perfringens 38,000 7 13,000 3 434,500 75
* Incidence of GP presentation in original IID study
Note: Based on the ability to detect at least a 20% reduction in incidence with 90% power and 95% precision. Required number of person-
years and GP practices (assuming an average GP practice size of 6,000 patients) by country, based on the relative populations of the 4 
countries.
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from both methods, for comparison with the first IID
Study and as a baseline for the future.
Comparison of incidence in the Prospective and Telephone 
Survey studies
The incidences of IID in the community and presenting
to general practice from the prospective studies will be
compared with those from the Telephone Survey (using
one month and one week recall). Incidence ratios will be
estimated for each age, sex and recall period.
Ethical approval to perform the IID2 Study
A favourable ethical opinion to perform the whole of the
study was granted by the North West Research Ethics
Committee (07/MRE08/5). Research management and
governance was then sought, and approval granted by all
relevant Research and Development Organisations across
the United Kingdom.
Discussion
Various aspects of the study design merit discussion.
First, in the Telephone Survey we have elected to use lan-
dlines as the means of recruiting participants. Although
fixed telephony has declined from a peak of 93% of
households in 2003, some 87% of households still had a
fixed line phone in the first quarter of 2009 (Ofcom, 2009
http://www.ofcom.org.uk/research/cm/cmr09/
cmr09.pdf). This compares with 92% of homes that own
one or more mobile phones. Much of this increase in
mobile telephony is thought to reflect an increase in
mobile phone ownership amongst children in previously
non-mobile owning households. The issue of the impact
of increasing use of mobile phones on epidemiological
surveys is a difficult one. The risk of introducing bias by
not using mobile phone numbers is offset by a number of
considerations:-
• the use of mobile phone numbers in such surveys
has not yet become standard and reliable sampling
frames for these are not easily available
• many mobile phone users are children and we can-
not contact children directly for ethical reasons
• it is not easy to localise mobile phones to a geo-
graphical area.
In general terms, people without fixed line phones tend
to be younger and of lower socio-economic status -
groups who tend not to respond well to surveys. It is thus
unclear whether use of mobile phone numbers would
help to mitigate selection bias [29]. However, to assess the
potential for bias introduced by only using landlines, peo-
ple recruited into the Cohort Study are asked about their
main method of telephony. Furthermore, we shall assess
the representativeness of the participants in the Tele-
phone Survey compared with the general population.
Secondly, in the Cohort Study we are not collecting
specimens from asymptomatic people in the community.
This was, however, undertaken in the first IID study and
provided very useful information on asymptomatic peo-
ple carrying potential pathogens [10]. Using data only
from IID cases to attribute illness to a particular organ-
ism can lead to an overestimation of prevalence, as some
cases may be excreting organisms that are not directly
responsible for their illness; comparing frequency of
organisms in cases and controls is the best way of estab-
lishing the pathogenicity of an organism [10]. It has
recently been shown that illness due to norovirus and
rotavirus is closely related to viral load [21]. Using PCR
based analysis and data from the first IID study, in which
a nested case-control study was performed within the
cohort study, we will be able to determine thresholds for
symptomatic infection versus asymptomatic excretion
using CT values [22]. The potential disadvantage of send-
ing specimens unrefrigerated by conventional post is that
labile organisms like C. jejuni may die off before the spec-
imen reaches the laboratory. However, this is offset by the
high sensitivity of using molecular methods in addition to
conventional culture techniques. It is possible that, using
molecular methods, we will find evidence of mixed infec-
tions, and indeed this was the case when PCR based tech-
niques were used to re-examine specimens from the first
IID study [28]. Using this approach may allow us to deter-
mine the contributions of those pathogens to patients'
symptoms. In addition the major research question of
"Has the incidence of IID in the community declined
since the mid 1990s?" can be answered by a comparison
of data from cases in this study with that from the first
IID study.
Thirdly, we recognise that recruiting people to studies
during a primary care consultation poses a number of
challenges - not the least of which is asking the GP to
remember the study in the midst of a busy clinic [30,31].
To address this we have developed posters and informa-
tion leaflets for waiting rooms and consultation rooms,
which give people who consult with IID symptoms the
opportunity to ask about the study during the consulta-
tion. They also serve to remind practice staff that the
study is taking place. We have also placed a referral pad in
each consulting room so that, should the GP or nurse
practitioner be too busy to take the patient through the
study material at the time of the consultation, the patient
can still be referred to the research nurse to receive infor-
mation about the study. Despite these measures we rec-
ognise that not all eligible cases will be invited to take
part. In the first IID study the records of 2,021 cases of
possible IID were examined, 1514 (75%) fulfilled the case
definition and 974 (64%) were included in the GP Presen-
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tation Study [10]. It is for this reason that we are auditing
recruitment to the IID2 Study in the Validation Study. We
will be able to adjust the final results, taking account of
under-ascertainment of cases i.e. those who should have
been recruited to the GP Presentation Study but were
not.
Fourthly we have used a very sensitive case definition.
This means that we may detect alterations in bowel habit
that are not necessarily due to gastrointestinal pathogens,
leading to a fairly large diagnostic gap (i.e. proportion of
specimens negative for gastrointestinal pathogens). Alter-
natively, the case definition may be insensitive since it
excludes subjects with diarrhoea of more than two weeks
duration and may therefore exclude infections with some
pathogens, particularly the protozoan parasites. However,
we are using the same case definition as was employed in
the first IID Study to allow us to compare rates between
the two studies directly. We should also be able to report
rates compatible with the proposed international case
definition.
Finally, the opinions of researchers worldwide are
divided over the optimal method(s) for undertaking com-
munity burden of IID studies. Rate estimates vary quite
considerably, depending on which methods are used. To
our knowledge, ours is the first study in which popula-
tion-based prospective and retrospective studies are
being conducted simultaneously. Therefore, in addition
to fulfilling our primary objectives we will be able to pro-
vide an objective evaluation of methods for determining
the community burden of IID in the future.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
SJOB, GR, PRH, JJG, FJB, JMcL, DST, CCT and LCR conceived the ideas for the
study. All authors participated in its design and co-ordination and helped to
draft the manuscript. SJOB, GR and LHL lead the prospective studies. PRH leads
the telephone survey. JJG, FJB and DST lead the laboratory studies. GKA, JMC,
MRE, KRN, GES and BS participate in the national surveillance studies. CCT and
LCR lead the analytical strategy. All authors have read and approved the final
manuscript.
Acknowledgements
We should like to thank the UK Food Standards Agency for funding the IID2 
Study (Project B18021), Julie Dodds, Hansa Shah, Valerie Brueton and Vania Gay 
at the MRC General Practice Research Framework, Mike van der Es and Lisa 
Irvine at the University of East Anglia, Kathryn Jackson and Emma Dixon at the 
University of Manchester, Alan Ridge, Katherine Mather and Bernard Wood at 
the Health Protection Agency Regional Laboratory in Manchester, Fenella Hal-
stead, Dalia Choudhury, Lisa Berry, Corine Amar, Ben Lopman and John Harris 
at the Health Protection Agency Centre for Infections, Laura Viviani, Suzanne St 
Rose and Julian Gardiner at the London School of Hygiene and Tropical Medi-
cine, Shirley Large at NHS Direct, Paul Cook for chairing the IID2 Study Execu-
tive Committee and Gael O'Neill, our Project Officer at the Food Standard 
Agency. We should also like to thank all the participants, research nurses, prac-
tice staff, telephonists, laboratory, research and administrative staff who are 
taking part in the IID2 Study.
Author Details
1School of Translational Medicine, University of Manchester, Manchester 
Academic Health Science Centre, Stopford Building, Oxford Road, Manchester, 
M13 9PL, UK, 2MRC General Practice Research Framework, Medical Research 
Council General Practice Research Framework, Stephenson House, 158-160 
North Gower Street, London, NW1 2ND, UK, 3School of Medicine, Health Policy 
and Practice, University of East Anglia, Norwich NR4 7TJ, UK, 4Centre for 
Infections, Health Protection Agency, 61 Colindale Avenue, London, NW9 5EQ, 
UK, 5Regional Microbiology Network, Health Protection Agency, HPA North 
West Manchester Laboratory, Oxford Road, Manchester, M13 9WL, UK, 
6Regional Microbiology Network, Health Protection Agency Yorkshire and the 
Humber, Leeds Laboratory, York Road, Leeds LS15 7TR, UK, 7Section of Public 
Health & Health Policy, University of Glasgow, 1 Lilybank Gardens, Glasgow, G12 
8RZ, UK, 8Department of Primary Care and Public Health, Cardiff University, 
Temple of Peace and Health, Cathays Park, Cardiff CF10 3NW, UK, 9Department 
of Epidemiology and Biomedical Research Unit (Gastro), University of 
Nottingham, Nottingham, NG7 2UH, UK, 10Health Protection Agency Real-time 
Syndromic Surveillance Team, Health Protection Agency, 6th Floor, 5 St Philip's 
Place, Birmingham, B3 2PW, UK, 11Health Protection Service Northern Ireland, 
Public Health Agency, McBrien Building, Belfast City Hospital, Belfast, BT9 7AB, 
UK and 12Department of Epidemiology and Population Health, London School 
of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK
References
1. Wheeler JG, Sethi D, Cowden JM, Wall PG, Rodrigues LC, Tompkins DS, 
Hudson MJ, Roderick PJ: Study of infectious intestinal disease in 
England: rates in the community, presenting to general practice, and 
reportedto national surveillance. The Infectious Intestinal Disease 
Study Executive.  BMJ 1999, 318(7190):1046-50.
2. de Wit MA, Koopmans MP, Kortbeek LM, Wannet WJ, Vinjé J, van Leusden 
F, Bartelds AI, van Duynhoven YT: Sensor, a population-based cohort 
study on gastroenteritis in the Netherlands: incidence and etiology.  
Am J Epidemiol 2001, 154(7):666-74.
3. Roy SL, Scallan E, Beach MJ: The rate of acute gastrointestinal illness in 
developed countries.  J Water Health 2006, 4(Suppl 2):31-69.
4. Hoogenboom-Verdegaal AM, de Jong JC, During M, Hoogenveen R, 
Hoekstra JA: Community-based study of the incidence of 
gastrointestinal diseases in The Netherlands.  Epidemiol Infect 1994, 
112(3):481-7.
5. MacKenzie WR, Hoxie NJ, Proctor ME, Gradus MS, Blair KA, Peterson DE, 
Kazmierczak JJ, Addiss DG, Fox KR, Rose JB, Davis JP: A massive outbreak 
in Milwaukee of Cryptosporidium infection transmitted through the 
public water-supply.  N Engl J Med 1993, 331:161-167.
6. Herikstad H, Yang S, Van Gilder TJ, Vugia D, Hadler J, Blake P, Deneen V, 
Shiferaw B, Angulo FJ: A population-based estimate of the burden of 
diarrhoeal illness in the United States: FoodNet, 1996-7.  Epidemiol 
Infect 2002, 129:9-17.
7. Hill DR: Health problems in a large cohort of Americans traveling to 
developing countries.  J Travel Med 2000, 7:259-266.
8. Imhoff B, Morse D, Shiferaw B, Hawkins M, Vugia D, Lance-Parker S, Hadler 
J, Medus C, Kennedy M, Moore MR, Van Gilder T: Burden of self-reported 
acute diarrheal illness in FoodNet surveillance areas, 1998-1999.  Clin 
Infect Dis 2004, 38(Suppl 3):S219-S226.
9. OzFoodNet Working Group: Foodborne disease in Australia: incidence, 
notifications and outbreaks. Annual report of the OzFoodNet network, 
2002.  Commun Dis Intell 2003, 27:209-43.
10. Food Standards Agency: A report of the study of infectious intestinal 
disease in England.  London: The Stationery Office; 2000. 
11. Hunter PR, Syed Q: Recall bias in a community survey of self-reported 
gastroenteritis undertaken during an outbreak of cryptosporidiosis 
strongly associated with drinking water after much press interest.  
Epidemiol Infect 2002, 128:433-438.
12. Strickland MJ, Crawford JM, Shen L, Wilkins JR: Time-dependent 
recordkeeping fatigue among youth completing health diaries of 
unintentional injuries.  J Safety Res 2006, 37(5):487-92.
13. Verbrugge LM: Health diaries.  Medical Care 1980, 18:73-95.
Received: 18 March 2010 Accepted: 5 May 2010 
Published: 5 May 2010
This article is available from: http://www.biomedcentral.com/1471-2288/10/39© 2010 O'Brien et l; licensee BioMed Central Lt . is an Op  Access articl  distributed under th  terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Medical Research Me hodol gy 2010, 10:39
O'Brien et al. BMC Medical Research Methodology 2010, 10:39
http://www.biomedcentral.com/1471-2288/10/39
Page 13 of 13
14. Gill LJ, Shand PAX, Fuggle P, Dugan B Davies SC: Pain assessment for 
children with sickle cell disease: improved validity of diary keeping 
versus interview ratings.  British Journal of Health Psychology 1997, 
2:131-140.
15. Marcus AC: Memory aids in longitudinal health surveys: results from a 
field experiment.  Am J Public Health 1982, 72:567-573.
16. Gillmore MR, Gaylord J, Hartway J, Hoppe MJ, Morrison DM, Leigh BC, 
Rainey DT: Daily data collection of sexual and other health-related 
behaviors.  The Journal of Sex Research 2001, 38:35-42.
17. Redline S, Wright EC, Kattan M, Kercsmer C, Weiss K: Short-term 
compliance with peak flow monitoring: results from a study of inner 
city children with asthma.  Pediatric Pulmonology 1996, 21:203-210.
18. Burkhart PV, Dunbar-Jacob JM, Rohay JM: Accuracy of children's self-
reported adherence to treatment.  Journal of Nursing Scholarship 2001, 
33:27-32.
19. Majowicz SE, Hall G, Scallan E, Adak GK, Gauci C, Jones TF, O'Brien S, Henao 
O, Sockett PN: A common, symptom-based case definition for 
gastroenteritis.  Epidemiol Infect 2008, 136(7):886-94.
20. Chisholm J: The Read clinical classification.  BMJ 300(6732):1092.
21. Phillips G, Lopman B, Tam CC, Iturriza-Gomara M, Brown D, Gray J: 
Diagnosing rotavirus A associated IID: Using ELISA to identify a cut-off 
for real time RT-PCR.  J Clin Virol 2009, 44(3):242-5.
22. Phillips G, Lopman B, Tam CC, Iturriza-Gomara M, Brown D, Gray J: 
Diagnosing norovirus-associated infectious intestinal disease using 
viral load.  BMC Infect Dis 2009, 9:63.
23. Boom R, Sol C, Wertheim-van Dillen P: Rapid purification of ribosomal 
RNAs from neutral agarose gels.  Nucleic Acids Res 1990, 18(8):2195.
24. McLauchlin J, Pedraza-Díaz S, Amar-Hoetzeneder C, Nichols GL: Genetic 
characterization of Cryptosporidium strains from 218 patients with 
diarrhea diagnosed as having sporadic cryptosporidiosis.  J Clin 
Microbiol 1999, 37:3153-3158.
25. Green J, Norcott JP, Lewis D, Arnold C, Brown DW: Norwalk-like viruses: 
demonstration of genomic diversity by polymerase chain reaction.  J 
Clin Microbiol 1993, 31:3007-3012.
26. Amar CFL, Dear PH, McLauchlin J: Detection and genotyping by real-
time PCR/RFLP analyses of Giardia duodenalis from human faeces.  J 
Med Microbiol 2003, 52:681-683.
27. Amar CFL, Dear PH, McLauchlin J: Detection and genotyping by 
conventional and real time PCR/RFLP analysis of Cryptosporidium 
species in human faeces.  Lett Appl Microbiol 2004, 38:217-22.
28. Amar CFL, East CL, Grant KA, Gray J, Iturriza-Gomara M, Maclure EA, 
McLauchlin J: Detection of viral, bacterial and parasitological RNA or 
DNA of nine intestinal pathogens in faecal samples archived as part of 
the English Infectious Intestinal Disease Study: assessment of the 
stability of target nucleic acid.  Diagn Mol Pathol 2005, 14:90-6.
29. Wilkins C, Casswell S, Barnes HM, Pledger M: A pilot study of a computer-
assisted cell-phone interview (CACI) methodology to survey 
respondents in households without telephones about alcohol use.  
Drug Alcohol Rev 2003, 22:221-5.
30. Wilson S, Delaney BC, Roalfe A, Roberts L, Redman V, Wearn AM, Hobbs 
FD: Randomised controlled trials in primary care: case study.  BMJ 2000, 
321(7252):24-7.
31. Bower P, Wallace P, Ward E, Graffy J, Miller J, Delaney B, Kinmonth AL: 
Improving recruitment to health research in primary care.  Fam Pract 
2009, 26(5):391-7.
32. Jensen A: Listeria monocytogenes isolation from human faecal 
specimens: experiments with the selective media, PALCAM and L-
PALCAMY.  Lett Appl Microbiol 1993, 16(1):32-5.
33. Grif K, Patscheider G, Dierich MP, Allerberger F: Incidence of fecal carriage 
of Listeria monocytogenes in three healthy volunteers: a one-year 
prospective stool survey.  Euro J Clin Microbiol Infect Dis 2003, 22:16-20.
34. Kageyama T, Kojima S, Shinohara M, Uchida K, Fukushi S, Hoshino FB, 
Takeda N, Katayama K: Broadly reactive and highly sensitive assay for 
Norwalk-like viruses based on real-time quantitative reverse 
transcription-PCR.  J Clin Microbiol 2003, 41:1548-1557.
35. Iturriza Gomarra M, Wong C, Blome S, Desselberger U, Gray J: Molecular 
characterization of VP6 genes of human rotavirus isolates: correlation 
of genogroups with subgroups and evidence of independent 
segregation.  J Virol 2002, 76:6596-6601.
36. Iturriza Gómara M, Simpson R, Perault AM, Redpath C, Lorgelly P, Joshi D, 
Mugford M, Hughes CA, Dalrymple J, Desselberger U, Gray J: Structured 
surveillance of infantile gastroenteritis in East Anglia, UK: incidence of 
infection with common viral gastroenteric pathogens.  Epidemiol Infect 
2008, 136(1):23-33.
37. Oka T, Katayama K, Hansman GS, Kageyama T, Ogawa S, Wu FT, White PA, 
Takeda N: Detection of human sapovirus by real-time reverse 
transcription-polymerase chain reaction.  J Med Virol 2006, 
78(10):1347-53.
38. Noel JS, Liu BL, Humphrey CD, Rodriguez EM, Lambden PR, Clarke IN, 
Dwyer DM, Ando T, Glass RI, Monroe SS: Parkville virus: a novel genetic 
variant of human calicivirus in the Sapporo virus clade, associated with 
an outbreak of gastroenteritis in adults.  J Med Virol 1997, 52:173-178.
39. Tiemessen CT, Nel MJ: Detection and typing of subgroup F 
adenoviruses using the polymerase chain reaction.  J Virol Methods 
1996, 59(1-2):73-82.
40. Best EL, Powell EJ, Swift C, Grant KA, Frost JA: Applicability of a rapid 
duplex real-time PCR assay for speciation of Campylobacter jejuni and 
Campylobacter coli directly from culture plates.  FEMS Microbiol Lett 
2003, 229:237-241.
41. Murphy NM, McLauchlin J, Ohai C, Grant KA: Construction and 
evaluation of a microbiological positive process internal control for 
PCR-based examination of food samples for Listeria monocytogenes 
and Salmonella enterica.  Int J Food Microbiol 2007, 120(1-2):110-9.
42. Frahm E, Obst U: Application of the fluorogenic probe technique 
(TaqMan PCR) to the detection of Enterococcus spp. and Escherichia coli 
in water samples.  J Microbiol Methods 2003, 52:123-131.
43. Amar CF, East CL, Gray J, Iturriza-Gomara M, Maclure EA, McLauchlin J: 
Detection by PCR of eight groups of enteric pathogens in 4,627 faecal 
samples: re-examination of the English case-control Infectious 
Intestinal Disease Study (1993-1996).  Eur J Clin Microbiol Infect Dis 2007, 
26(5):311-23.
44. Møller Nielsen E, Thorup Andersen M: Detection and Characterization of 
Verocytotoxin-Producing Escherichia coli by Automated 5' Nuclease 
PCR assay.  J Clin Microbiol 2003, 41:2884-2893.
45. Grant KA, Kenyon S, Nwafor I, Plowman J, Ohia C, Halford-Maw R, Peck M, 
McLauchlin J: The identification and characterisation of Clostridium 
perfringens by real time PCR, location of enterotoxin gene and heat 
resistance.  Foodborne Pathog Dis 2008, 5:629-39.
46. Huang H, Weintraub A, Fang H, Nord CE: Comparison of a commercial 
multiplex real-time PCR to the cell cytotoxicity neutralization assay for 
diagnosis of Clostridium difficile infections.  J Clin Microbiol 2009, 
47(11):3729-31.
47. Novak-Weekley SM, Marlowe EM, Miller JM, Cumpio J, Nomura JH, Vance 
PH, Weissfeld A: Clostridium difficile Testing in the Clinical Laboratory 
using Multiple Testing Algorithms.  J Clin Microbiol 2010, 48(3):889-893.
48. Swindells J, Brenwald N, Reading N, Oppenheim B: An Evaluation of 
Diagnostic Tests for Clostridium difficile Infection.  J Clin Microbiol 2010, 
48(2):606-608.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2288/10/39/prepub
doi: 10.1186/1471-2288-10-39
Cite this article as: O'Brien et al., Methods for determining disease burden 
and calibrating national surveillance data in the United Kingdom: the second 
study of infectious intestinal disease in the community (IID2 study) BMC Med-
ical Research Methodology 2010, 10:39
